US2003176347A1PendingUtilityA1
Remedies for amyotrophic lateral sclerosis
Priority: May 14, 2003Filed: Feb 28, 2001Published: Sep 18, 2003
Est. expiryMay 14, 2023(expired)· nominal 20-yr term from priority
A61K 38/1833A61K 48/005A61K 48/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention presents a therapeutic agent (and progress suppressant) for amyotrophic lateral sclerosis (ALS) containing HGF and/or HGF gene as active ingredient. HGF has an effect of improving the motor function of ALS and life span through two actions, that is, direct neuronutrient factor activity on motoneurons, and indirect improving action of glutamate cytotoxicity on motoneurons by maintaining the level of glutamate transporter in astrocytes. Hence, HGF and/or HGF gene can be used as an effective therapeutic agent not known in the past.
Claims
exact text as granted — not AI-modified1 . A remedy for amyotrophic lateral sclerosis (ALS), containing HGF and/or HGF gene as active ingredient.
2 . A progress suppressant for ALS, containing HGF and/or HGF gene as active ingredient.
3 . An induction suppressant of caspase-1 in motoneurons, containing HGF and/or HGF gene as active ingredient.
4 . A phosphorylation promoter of Akt in spinal cord, containing HGF and/or HGF gene as active ingredient.
5 . A decrease suppressant of glial-specific glutamate transporter (EAAT2/GLT-1) in astrocytes, containing HGF and/or HGF gene as active ingredient.Join the waitlist — get patent alerts
Track US2003176347A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.